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Abstract
Background: Identification of MET genetic alteration, mutation, or amplification in oropharyngeal squamous cell carcinoma
(OPSCC) could lead to development of MET selective kinase inhibitors. The aim of this study was to assess the frequency and
prognostic value of MET gene mutation, amplification, and protein expression in primary OPSCC.
Methods: A retrospective chart review was conducted of patients treated for single primary OPSCC between January 2007
and December 2009. Pre-treatment OPSCC tissue samples were analyzed for MET mutations, gene amplification, and
overexpression using Sanger sequencing, FISH analysis, and immunohistochemistry respectively. Univariate and multivariate
analyses were used to analyze correlations between molecular abnormalities and patient survival.
Results: 143 patients were included in this study. Six cases (4%) were identified that had a genetic variation, but previously
described mutations such as p.Tyr1235Asp (Y1235D) or p.Tyr1230Cys (Y1230C) were not detected. There were 15 high
polysomy cases, and only 3 cases met the criteria for true MET amplification, with $10% amplified cells per case.
Immunohistochemistry evaluation showed 43% of cases were c-MET negative and in 57% c-MET was observed at the tumor
cell level. Multivariate analysis showed no significant association between MET mutation, amplification, or expression and
survival.
Conclusions: Our study shows a low frequency of MET mutations and amplification in this cohort of OPSCC. There was no
significant correlation between MET mutations, amplification, or expression and patient survival. These results suggest that
patient selection based on these MET genetic abnormalities may not be a reliable strategy for therapeutic intervention in
OPSCC.
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Introduction
Head and neck cancer (HNC) is the sixth most common cancer
in the world, with approximately 635,000 new cases worldwide in
2008.[1] Oropharyngeal cancer (OPC) was responsible for an
estimated 36,540 new cases and 7,880 deaths in 2010 in the
United States[2], and 91,900 new cases and 41,700 deaths in 2008
in Europe[3]. The incidence is higher in males (3.9% of total
cancers) than females (1.6% of total cancers).[3] OPC includes
tumors arising within the posterior pharyngeal wall, soft palate,
tonsillar region, and the base of the tongue. The majority of these
tumors (.95%) are squamous cell carcinomas (SCC) of mucosal
origin.[4] A rise in the incidence of OPC has been observed in the
developed world, particularly in North America, which may be
explained by oncogenic Human Papilloma Virus (HPV) infection.
HPV-positive and HPV-negative OPC’s represent distinct sub-
groups. The first has a better prognosis, whereas the second is
associated with tobacco and alcohol abuse and has a poorer
prognosis.[5]
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MET is a receptor tyrosine kinase located on chromosome 7q31
that encodes several functional domains: the semaphoring (SEMA)
domain (ligand-binding), juxtamembrane (JM) domain (regulato-
ry), and the tyrosine kinase (TK) domain.[6,7] The only known
ligand for MET is the hepatocyte growth factor/scatter factor
(HGF/SF).[8] HGF/MET signalling leads to various cellular
responses, such as increased cell growth, cell motility, survival,
angiogenesis, wound healing, tissue regeneration, and invasion/
metastasis.[6,7] MET activation can occur via multiple molecular
events including: gene mutation, gene amplification, protein
overexpression, or ligand dependent autocrine and paracrine
loop.[9–12]
MET is overexpressed in various solid tumors (eg. small cell lung
cancer, non-small cell lung cancer, gastric cancer, renal cell
carcinoma, and breast cancer)[6,13–17] and its overexpression is
often associated with an aggressive phenotype and poor prognosis.
In head and neck squamous cell carcinoma (HNSCC) specifically,
several reports indicate 70% to 100% MET overexpression,
suggesting that the HGF/MET pathway plays a role in carcino-
genesis.[8,12,18–21] HGF/MET signalling could also interfere
with response of oropharyngeal squamous cell carcinoma
(OPSCC) to radiotherapy (RT).[22]
Furthermore, MET genetic alterations have been previously
reported in HNC. MET Y1235D mutation (also known as
Y1253D) was found in 15 out of 138 patients (11%) with
OPSCC[23], and in 21 out of 152 patients (14%) with
HNSCC[24], suggesting a relatively high prevalence of this
mutant in the OPC. This MET Y1235D mutation and another
mutation in the MET activation loop (Y1230C) were also detected
in neck lymph nodes metastases from a primary HNSCC
tumor.[25] Recently, another epidemiological study reported
novel mutations in the SEMA, JM, and TK domains of MET in
13.5% of the cases, and an increased MET gene copy number
(.10 copies) in 3 out of 23 cases.[8]
The identification of a cancer type in which MET genetic
alteration, mutation, or amplification is present in a significant
subset such as OPSCC is of high interest. This could lead to
development of MET selective kinase inhibitors, since genetic
alterations are often responsible for oncogenic addiction. There
are various recent clinical trials that have already demonstrated
the effect of MET inhibitors in patients with a variety of advanced
or metastatic tumors, including non-small-cell lung cancer, and
breast, prostate, liver, and renal cancer.[10] The aim of this study
is to determine the frequency and prognostic value of MET gene
mutation, amplification, and protein expression in OPSCC.
Materials and Methods
Ethics Statement
The Gustave Roussy Cancer Institute (IGR) Institutional
Review Board gave approval for this study. Written informed
consent was obtained from included patients, and patient
confidentiality was protected throughout the study.
Patient selection
A retrospective chart review was conducted for patients treated
for a single primary OPSCC between January 2007 and
December 2009 at the IGR. Patients with recurrences, multiple,
synchronous, or metachronous lesions were excluded from this
study.
Pretreatment tissue samples were retrieved from the IGR
Biobank. Most tissue samples were obtained by surgical biopsy and
fixed using AFA, while tissue samples obtained during surgical
resection were fixed with 10% formalin. Based on hematoxylin
and eosin (H&E) staining, tissue samples with at least 70% tumor
cells were selected. DNA sequencing, fluorescence in situ
hybridization (FISH) assay, immunohistochemistry (IHC), and
HPV detection were done in different laboratories, in a strictly
blind fashion.
DNA extraction and sequencing
Genomic DNA was extracted from 10 to 20 mm tissue bloc
sections from tumors using the DNeasy Blood and tissue kit
(QIAGEN, Hilden, Germany) according to the manufacturer’s
instructions. The full coding sequences of MET exons 2 and 13
through 21 (NM_000245.2), exons already described as known
locations for oncogenic mutations, were analyzed. Sanger
sequencing was done following polymerase chain reaction (PCR)
amplification of target exons. The primer sequences are reported
in Table 1. The sequencing reactions were carried out using the
BigDye Terminator Cycle Sequencing Kit as indicated by the
manufacturer (Applied Biosystems, Forster City, CA). Sequencing
reactions were analyzed on a 48-capillary 3730 DNA Analyzer.
The sequence alignment and analysis were performed with
SeqScape software (Applied Biosystems). All detected mutations
were confirmed at least once with independent PCR amplification.
Detection of HPV DNA viral load using RealTime qPCR
Tests were done to detect the three oncogenic HPV strains (16,
18, and 33) as well as the reference gene gACTB (b-actin) as
previously described by Melkane et al.[26] Briefly, quantitative
HPV DNA viral load measures were available, and a semi-
quantitative viral load categorization was obtained according to
individual Cycle Thresholds (CT); CT$45: 2, CT,45: +. All
mildly HPV-positive samples (38#CT,45) were confirmed on
independent testing.
MET gene FISH assay
FISH for the MET gene was performed on 4 mm tumor
sections, using the ZytoLight SPEC MET/CEN 7 Dual Color
Probe (ZytoVision GmbH, Bremerhaven, Germany) according to
the manufacturer’s instructions. SNU-5 (ATCCH CRL-5973TM)
cell line xenografts bearing MET amplification were used as
positive control samples to set up the FISH staining protocol.
Briefly, the probe was co-denatured for five minutes at 84uC on
the slide, and then incubated overnight at 44uC. Slides were
washed with post-hybridization wash buffer (0.5X SSC/0.1%
SDS) for five minutes at 37uC, after which they were air-dried and
counterstained with DAPI dissolved in an anti-fade mounting
solution. At least 100 tumor cells were analyzed, and the number
of fluorescent signals within the nuclear boundary of each
evaluable interphase tumor cell was counted using an Axiophot-
ZEISS fluorescent microscope at 10006 magnification. Only
nuclei with unambiguous centromeric (D7Z1 locus) hybridization
red signals (as control) and MET (7q31) probe green signals were
scored. Tumors were classified as previously described by Capuzzo
et al.[27] Briefly, FISH negative was when there were two or three
copies of the MET gene present in major clone of tumor cells, or
when four MET gene copies were present in less than 40% of
tumor cells. The term ‘high polysomy’ was applied if four to six
copies of the MET gene were present in more than 40% of tumor
cells. In order to declare ‘gain of gene’, more than one or two
supplementary copies of the MET gene (compared to the
centromeric probe) had to be present in tumor cells. Amplification
was defined as a MET gene to centromere ratio .2.
MET for Patient Selection for Treatment in OPSCC
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IHC
Immunostaining. We performed MET and p-MET immu-
nostaining using serial tissue sections. Briefly, antigen retrieval was
performed with Cell Conditioning 1 (CC1) buffer at 95uC for 8
minutes, and then at 100uC for 28 minutes. After the endogen
biotins blocking step, slides were incubated with the primary anti-
antibody for one hour at 24uC for the rabbit anti-human c-MET
(final dilution 1/50, clone SP44, reference M3444, Spring
Bioscience, USA or clone CVD13, reference 18-2257, Invitrogen,
USA) and at 37uC for anti-p-MET (Tyr1234/1235) (final dilution
1/50, clone D26, reference 3077, Cell Signaling Technologies,
USA). A post-fixation step with glutaraldehyde (0.05% in NaCl
0.9% w/v) for 4 minutes at 24uC was done. For MET detection,
the secondary antibody biotin-SP-conjugated Affinipure goat anti-
rabbit (reference 111-065-003, batch 84328, Jackson ImmunoR-
esearch Laboratories, Inc, USA) was incubated at 24uC for 32
minutes at 0.5 microg/mL. For p-MET, the secondary antibody
biotin free peroxidase multimer anti-rabbit UltraMapTM was
incubated at 24uC for 16 minutes. Immunostaining was done with
3,3-diaminobenzidine tetrahydrochloride (DAB) from DAB-
MapTM chromogenic detection kit according to manufacturer’s
recommendations. A counter-staining step was done with hema-
toxylin and blueing reagent was applied. Stained slides were
dehydrated and coverslipped with cytoseal XYL (8312-4, Richard-
Allan Scientific, USA).
Xenograft tumors. Investigation using xenograft tumors was
done to determine the impact of fixative type on p-MET detection.
SNU-5 (ATCCH CRL-5973TM) tumor cell line xenografts were
divided into two groups, and placed in neutral buffered formalin
(HT50112, Sigma-Aldrich, France) or AFA (acetic acid, formal-
dehyde, alcohol) fixative.
Image analysis. Immunostained slides were scanned using
the ScanScope XT system (Aperio Technologies, Vista, CA).
Digitized images were captured using the ImageScope software
(version 10.2.2.2319, Aperio Technologies) at 206magnification.
IHC scoring. Staining evaluation included the histological
site of reactivity, main type of reactive cell, staining, intensity, and
cell staining frequency. The negative samples were scored as 0+.
The positive samples were scored with a scale of intensity from 1+
to 3+. Ranges of intensities were described as weak (0 to 1+),
moderate (1+ to 2) and strong (2+ to 3+). Cell frequency was the
percentage of immunostained cells, and was estimated by
observation by a histologist as the median per sample. The cell
frequency was divided into five categories of proportion score: 1
(0–5%), 2 (6–25%), 3 (26–50%), 4 (51–75%) and 5 (76–100%).
Statistical analyses
Descriptive statistics were used to summarize the study cohort.
The Kaplan-Meier method was used to estimate overall survival
(OS), progression free survival (PFS) and specific survival (SS). The
evaluation and selection of covariates to be included in the
multivariate model for survival was done as follows. The first step
was to assess the correlation between covariates, in order to avoid
keeping in the model two covariates when they are highly
correlated and bring similar information. A threshold of 0.4 was
used for this selection. Then, univariate analyses were conducted
using Cox Proportional Hazards Model on the above factors to
identify the variables with the highest correlation with OS, PFS,
and SS. Lastly, the multivariate Cox Proportional Hazards Model
was run using the stepwise procedure with a variable entry of 5%
level and a variable removal at each step of 10% level. When two
covariates were highly correlated according to the threshold
previously defined, only the most significant one in univariate
analysis was kept for the multivariate analysis.
Results
Patient and tumor characteristics
Medical files of 150 consecutive patients with OPSCC were
reviewed. Of these patients, three presented with synchronous
tumor lesions, three had recurrent disease, and one patient had
insufficient tissue material available for laboratory studies, and
were excluded. There were 143 patients included in this study
(Table 2). The majority of patients were male (69%), and the









S327 2 AATGGTATAGGTCTTTCAGTTTTCTCTTC 29 TGTAGAATGACATTCTGGATGGGT 24
S328 2 AGTCCGAGATGAATGTGAATATGAAG 26 AGCCATGTTGATGTTATCTTTCCA 24
S150 2 GATTGTTTCCCATGTCAGGACTG 23 TGGTATTGCCTACAAAGAAGTTGATG 26
S151 2 CTGTGTGGTGAGCGCCC 17 AACCTGATTATTCTTGTGTGAAAAGTCT 28
S152 2 CGGTCCAAAGGGAAACTCTAGAT 23 ACATATTTGATAGGGAATGCACACAT 26
S153 2 TAGGAGCCAGCCTGAATGATG 21 CTGCAACTATTTTGGATAAACACCAT 26
S329 13 CAACCTGTGTAGTACAAATATCTATCATGG 30 GACAATCTTAAACTGTAATGACTGTGTTCTTA 32
S022 14 CACTGGGTCAAAGTCTCCTGG 21 TGTCACAACCCACTGAGGTATATGT 25
S330 15 TTTCAGTCCCCATTAAATGAGGTTT 25 GGCCAAAGATAAAATGCTTACTGGA 25
S023 16 AAAATGAAGCTCATAAAGGGTTTGA 25 GGCCCATAATTTCAGTGGTAGC 22
S154 17 CTCTTCCTATCTAAATTTGACAAAAGTATTCA 32 GAAGGGATGGCTGGCTTACA 20
S155 18 CTTGAGCCATTAAGACCAAACTAATTT 27 ACAGTGGGAAACAGATTCCTCC 22
S024 19 AATTATTCTATTTCAGCCACGGGT 24 AAAACTGGAATTGGTGGTGTTGA 23
S331 20 TTAGTTACCAAGACCTACTGATTTCCTTTC 30 TTTGAAGGCAGGCATTTCTGTA 22
S332 21 TTTACAGAAATGCCTGCCTTCAA 23 TCAGGCAGTGAAAAAACCATTG 22
*MET proto-oncogene (hepatocyte growth factor receptor); other aliases: AUTS9, HGFR, RCCP2, c-MET
doi:10.1371/journal.pone.0084319.t001
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overall mean age of presentation was 59 years (range 27 to 87
years). Most patients had previous tobacco exposure, with 47/143
active smokers and 48/143 former smokers (quit for $6 months).
Of the patients with previous alcohol use, 42/143 were active
consumers and 18/143 were former consumers (quit for $6
months). Fifty-nine patients (41%) experienced combined alcohol
and tobacco exposure (either active or past), whereas 47 patients
(32%) had never been exposed to either carcinogen. Seventy
tumors (79%) display p16 staining. Nevertheless, because we have
previously shown that HPV DNA viral load status had a higher
prognostic value than the p16 expression status, we focus on HPV
DNA status for analysis.[26] Eighty-eight tumors (62%) were
detected with HPV DNA on qPCR, irrespective of the viral load
level, the involved HPV serotype, or the exclusive or combined
infection status. There were 55 (38%) cases that were HPV
negative.
The majority of tumors were localized in the tonsillar fossae and
pillars (63%), or at the base of the tongue (14%). The macroscopic
aspect of the tumors was exophytic in 88 cases (62%), and
ulcerative or infiltrative in 55 cases (38%). Histopathologically,
approximately half of the tumors was well-differentiated, and the
other half was moderately or poorly differentiated. The majority of
patients presented with T3 or T4 stage tumors, and had N1-N3
lymph node metastases. There were six patients (4%) with distant
metastases at the time of evaluation, all with pulmonary
metastases. According to the 2010 AJCC classification system,
29/143 patients (20%) presented with early-stage (stage I and II)
tumors, while a majority of 114/143 patients (80%) had advanced
stage (stage III and IV) disease.
Most of the patients (136/143, 95%) in this study were treated
in a curative setting. Patients were treated by RT; either
exclusively (31/143 patients, 21%), or by concomitant chemor-
adiotherapy (CRT) (75/143 patients, 52%), and surgery; either
exclusively (15/143 patients, 11%), or followed by adjuvant RT or
CRT (16/143 patients, 11%). The remaining six patients (5%)
with distant pulmonary metastases were offered treatment with
palliative chemotherapy.
MET mutations in OPSCC
Exons 2, 13, 14, 15, 16, 17, 18, 19, 20, and 21 were analyzed in
all 143 cases, but due to low tissue sample quality, some cases had
several failed PCR’s (.5 failures) and were removed from further
analyses. Overall, six cases (4%) were identified that had a genetic
variation (Table 3).
Four of these mutations were located on exon 2, one on exon
15, and one on exon 18. The p.Val136Ile mutation has been
previously detected once before in a kidney carcinoma case[6],
and the p.Ala347Thr mutation has been described in lung
squamous cell carcinoma[28]. The p.Glu312Lys, p.Thr1036Ile,
and p.Cys1210Arg variations have not yet been described in
literature and are novel somatic variant with unknown pathoge-
nicity.[29] Previously described mutations such as p.Tyr1235Asp
(Y1235D) or p.Tyr1230Cys (Y1230C) in exon 19 were not found.
Of the six variations, four were expected to affect protein function
based on the SIFT classification system, three of which had
predicted damaging effects according to the PolyPhen-2 scoring
system.
MET amplification in OPSCC
FISH analysis was performed for 128 out of 143 cases, because
there was insufficient tissue from the remaining cases for further
analysis. Hybridization was successful for 97 out of 128 cases. Of
those cases, 39 were considered normal, 17 had monosomy of
chromosome 7 or deletion of MET gene, 23 had low polysomy,
and 15 had high polysomy of chromosome 7 (Table 4, Figure 1).
In the high polysomy category, two cases were detected as gene
amplifications, but the amplified clone presented only 4–5% of
cells and thus did not meet the criteria to be included in the
‘‘amplified’’ category. Only three cases met the criteria for true
MET amplification, with $10% amplified cells per case.
MET protein expression in OPSCC
IHC evaluation was done for 113 cases, and a total of 107 cases
passed the quality controls and were included (Table 5). Forty six
cases (43%) were c-MET negative. c-MET protein was observed
in 61 cases (57%) at the tumor cell level. Of the 61 c-MET positive
cases, immunostaining was localized at the membrane 6
cytoplasm level in 50 cases (82%), with moderate expression
(median intensity 1+ to 2+, and median cell frequency 50% to
75%). In the other 11 cases (18%), immunostaining was observed
















Tonsillar fossae and pillars 90 (63)
Base of tongue 21 (14)
Glosso-tonsillar sulcus 11 (8)
Valleculae 8 (6)
Soft palate 7 (5)












Stage I/II 29 (20)
Stage III/IV 114 (80)
*American Joint Committee on Cancer
doi:10.1371/journal.pone.0084319.t002
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only at the cytoplasm level, with moderate expression (median
intensity 1+, and median cell frequency 75% to 100%; Figure 2).
Detection of pYY1234-1235MET was observed in two cases (3%),
but in non-tumor cells (at margin of tissue sample). AFA fixation
resulted in complete disappearance of p-MET immunostaining
(Figure 2). p-MET analysis was therefore only done for formol-
fixed tissue.
Survival analysis
The median follow-up time was 2.6 years (min. 11 days and
max. 13.9 years), and there were 57/143 (40%) deaths observed.
The median OS was 5.3 years. The probabilities of surviving (95%
confidence interval) at one, two, and three years were 82.4% (CI:
76.1–88.7), 67.3% (CI: 59.5–75.1) and 64.5% (56.5–72.6)
respectively. There were 71 oncological events (tumor progression,
loco-regional or distant recurrence, and death) observed in the 143
patients. The median PFS was 4.4 years. The probabilities of
having an oncological event (95% confidence interval) at one, two,
and three years were 68.3% (CI: 60.7–76.0), 61.8% (CI: 53.8–
69.9), and 57.5% (CI: 49.2–65.8) respectively. There were 30/143
(21%) cancer-related deaths. The positive HPV status, alcohol
exposure, high tumor differentiation, T3/T4 staging, N1-3
staging, presence of metastases and advanced disease (AJCC
classification III/IV) were significant at 5% for OS in the
univariate Cox Proportional Hazards Model. Except N1-3 staging,
these variables were also significant for PFS (at 5%). Univariate
analysis did not show any significant association between OS, PFS,
or SS and MET mutations, MET amplification, or MET
overexpression. It is notable that MET positive cases were not
specifically distributed in either the HPV positive or HPV negative
groups. The multivariate analysis did not show any significant
Table 3. The location and predicted effect of each MET variation found, numbered from the reference sequence NM 000245.2.
Variation # of cases Location Align-GVGD{ [48] SIFT` [49] PolyPhen-2[50]
p.Val136Ile 1 Semaphoring domain Class C0 (benign/no effect) tolerated benign/no effect
p.Glu312Lys 1 Semaphoring domain Class C0 (benign/no effect) tolerated benign/no effect
p.Thr1036Ile 1 Juxtamembrane domain Class C15 (damaging) affects protein function benign no effect
p.Cys1210Arg 1 Kinase domain Class C0 (benign/no effect) affects protein function probably damaging
p.Ala347Thr 2 Semaphoring domain Class C55 (damaging) affects protein function probably damaging
Mutation Chromatograms include reference sequences and variant description sequence variations described using IUPAC code (http://www.insdc.org/).
{Align-Grantham Variation Grantham Deviation.
`Sorts Intolerant From Tolerant.
doi:10.1371/journal.pone.0084319.t003
Figure 1. FISH with two color probes: chromosome 7 centromere (green) and MET gene (red). A) True MET gene amplification in 10% of
cells: 4–8 centromere signals and 16–20MET signals, ratio.2.0. B) High polysomy: the same number of control andMET gene spots were seen in 15%
of giant cells, ratio is 1.0. C) Chromosome 7 monosomy: only one control and one MET signal were detected for this case. In some cells there is only
one signal (or no signal) due to a nuclei section. D) Normal hybridization pattern: two control spots and two MET gene spots. Again, some cells show
only one of two signals due to a nuclei section.
doi:10.1371/journal.pone.0084319.g001
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association between OS, PFS, or SS and MET mutations, MET
amplification, or MET overexpression.
Discussion
The aim of this study was to determine the frequency and
prognostic value ofMET abnormalities including DNA mutations,
gene amplification, and protein expression in primary OPSCC.
Our study shows a low frequency of MET mutations and MET
amplification in OPSCC. There was no significant correlation
between MET mutations, amplification, or expression and patient
survival.
In our study six cases were identified with MET genetic
variations, four of which have not been previously described,
though the clinical relevance of these variations remains unclear.
Unfortunately, non-tumor tissue was not available to confirm if
those mutations were somatic. Overall, our MET mutation
incidence (4%) was low compared to a number of other studies.
For example, Seiwert et al. found a 13.5% mutation incidence in
the semaphoring, juxtamembrane, and tyrosine kinase domains of
the MET gene in 66 HNSCC tumor tissues, as well as MET over
expression in 84% of samples.
Previously described HNSCC mutations such as p.Tyr1235Asp
(Y1235D)[23–25] and p.Tyr1230Cys (Y1230C)[25] were not
detected in our study. In a study investigating the prevalence
and clinical impact of the Y1253D mutation in patients with
OPSCC treated by radical RT, the mutation was detected in 15/
138 tumors (10.9%). Also, survival analysis showed a significant
correlation between Y1253D mutation and impaired local tumor
control.[23] Another study by Ghadjar et al. detected Y1253D
mutation in 21 tumors in 152 patients (14%) with HNSCC and
observed an association with decreased distant metastasis-free
survival.[24] On the other hand, a set of 12 oral SCC’s were
examined for mutation and while overexpression of the MET
receptor was present in all cases, point mutations were not
detected.[20]
Studies investigating MET mutations use different DNA
detection techniques. Our Sanger sequencing approach is known
to detect mutation from 20–30% of mutated DNA. Our cohort
included only samples with more than 70% of tumor cells.
Nevertheless, our Sanger approach does not detect minor clones
representing less than 20% of the tumor cell, but can detect
unexpected mutations. More sensitive techniques such as the
technique used by Aebersold et al.[23] can detect minor clones,
but can only detect mutations that are targeted specifically. We
Table 4. Fluorescence in situ hybridization results.
Gene status # of cases Classification
Gene amplification 3 +
High polysomy 15 +
Normal 39 2
Monosomy/deletion 17 2
Low polysomy 23 2
Total 97
doi:10.1371/journal.pone.0084319.t004
Figure 2. IHC staining for c-MET and pYY1234-1235 MET in OPSCC specimens. Moderate (A) and strong (B) membranous and cytoplasm c-
MET immunostaining in tumor cells. No p-MET immunostaining was observed in serial section (C and D). (original magnification620).
doi:10.1371/journal.pone.0084319.g002
Table 5. Immunohistochemistry results[26].
Parameter n (%)
Analyzable cases 107 (100)
c-MET negative cases 46 (43)
c-MET positive cases 61 (57)
Membrane with or without cytoplasm expression 50 (82)
Cytoplasm expression 11 (18)
p-MET positive cases 2 (3)
doi:10.1371/journal.pone.0084319.t005
MET for Patient Selection for Treatment in OPSCC
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could hypothesize that the technique used in our study may have
yielded a relatively lower DNA mutation frequency than a more
sensitive technique, if MET mutations are mainly present in minor
clones. One the other hand, we could also stipulate that the
present French cohort had a lower rate of MET mutation that
other published cohorts.
We also found a low frequency of amplification, with no
correlation with patient survival. Out of 97 cases, there were only
three cases that met the criteria for trueMET amplification and 15
cases with high polysomy. A previous study found .10 MET gene
copies in 3 of 23 (13%) HNSCC tumor tissues.[8] In other studies,
MET gene amplification has been associated with poor prognosis
in gastric and lung cancer. Lee et al. recently found 61 MET high
polysomy and 13 MET gene amplification cases in a cohort of 438
gastric carcinomas. In their study, gene amplification correlated
with a poor prognosis.[14] In another study concerning gastric
cancer patients, c-MET amplification again correlated and poor
survival.[15] In a cohort of 380 non-small cell lung carcinoma
cases, Park et al. found that an increase of MET gene copy
number, present in 11.1% of patients (high polysomy 8.7% and
gene amplification 2.4%), was a negative prognostic factor for
survival.[13] The relatively low frequency of MET mutations and
amplification in this OPSCC study cohort could be explained,
because MET may play a larger role in disease progression in
other types of cancer, such as gastric or lung cancer.
Another possible explanation for the low frequency of MET
mutations and amplification in our study cohort could be that
tissue samples were from primary OPSCC’s, and not from
metastases. There is evidence from previous studies that MET
mutations are primarily involved in tumor progression to the
metastatic phase.[9,30–36] A study by Di Renzo et al. showed that
in 4/15 HNSCC cases, activating MET mutations undergo clonal
expansion during metastatic spread, as their frequency increased
from 2% in the primary tumors to 50% in the metastases.[25]
MET overexpression was also found to be significantly higher in
tumor stages associated with enlarged or multiple (N2-N3) lymph
node metastases.[37] These findings indicate that the frequency of
MET molecular abnormalities could be higher in metastatic tissue
than in primary tumors, such as the tissue samples studied in our
cohort.
Protein expression analysis showed that out of 107 analyzable
cases, 46 cases (43%) were c-MET negative, and 61 cases (57%)
were c-MET positive at the tumor cell level. We found no
significant relationship between MET expression and survival.
This is in contrast with previous studies showing that MET
expression is an early event in HNC carcinogenesis[38], and has
an association with a poorer overall survival rate[19,39]. Later,
reports describe that compartment localization of c-Met is linked
to differentiation and stage of OPSCC tumors.[19] In one study,
HNSCC’s and their metastases were analyzed, showing that MET
expression was increased from 2- to 50-fold in about 70% of
tumors.[37] Kim et al. previously reported that elevated HGF/c-
MET expression in HNSCC correlated with tumor progres-
sion[40], and later showed that survival was significantly affected
in patients with c-MET expression in SCC of the oral
tongue[21,41].
In previous studies analyzing MET expression by IHC, various
guidelines were used to classify data. For example, different cut-off
values have been used to determine a positive result, such as MET
expression in .10% of tumor cells[42] or MET expression in
.30% of tumor cells[43]. These variations in data interpretation
can cause the same raw data to yield different (possibly misleading)
conclusions.
Unfortunately in our study, analysis of p-MET expression was
only possible for select cases, since the AFA fixative caused
complete disappearance of p-MET immunostaining. In the future,
AFA fixative must be avoided when p-MET IHC is done on
archival biopsies. Another factor that may have affected the
incidence of MET molecular abnormalities was a relatively large
number (62%) of HPV positive patients in our sample set. HPV
dependant carcinogenesis may partially explain the relatively low
incidence of MET abnormalities. It is even possible that HPV is a
stronger predictive biological marker than MET. [4,44–46] Our
data does not suggest a relationship between HPV status andMET
abnormalities.
Our study indicates that MET may not be a reliable prognostic
biological marker in primary OPSCC, and therefore that anti-
MET therapy may not be the ideal therapeutic option for these
types of tumors. Except for HPV status, we lack reliable diagnostic
and prognostic molecular markers for HNSCC, including OSCC.
Screening for MET molecular abnormalities in primary OPSCC
may not be efficient, partly because previous studies have
indicated that MET abnormalities are predominantly detected in
case of metastases. Detection of MET abnormalities might be
more appropriate as a marker of response to treatment. In a pilot
study, Druzgal et al. compared pre-treatment and post-treatment
cytokine levels in HNSCC, and found evidence for a strong
relationship between HGF serum levels and both therapeutic
response and survival.[47] Uchida et al. studied HGF/MET in oral
SCC and found significantly higher HGF concentrations in
metastatic cancer tissues, than non-metastatic or normal tissue.
A decline in serum HGF was seen in tumor-free survivors.[30]
Dysregulation of the MET pathway plays a role in various human
cancers, though ‘MET addiction’ only occurs in a small percentage
of these cancers. There are tumors that only partially depend on
MET signaling for growth and metastasis, which may be more
difficult to detect using biomarkers.[11] Identification of tumors
carrying the relevant genetic abnormality and methods for patient
stratification according to HGF/MET expression requires further
investigation to guarantee clinical benefit.[10]
Conclusions
There was a low frequency ofMET mutations and amplification
in this OPSCC cohort. There was no association between MET
molecular abnormalities and patient survival. Our results indicate
that these MET genetic abnormalities may not be reliable
prognostic biological markers in OPSCC for patient selection for
anti-MET therapy.
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